Issue 5, 2023

XFCT-MRI hybrid multimodal contrast agents for complementary imaging

Abstract

Multimodal contrast agents in biomedical imaging enable the collection of more comprehensive diagnostic information. In the present work, we design hybrid ruthenium-decorated superparamagnetic iron oxide nanoparticles (NPs) as the contrast agents for both magnetic resonance imaging (MRI) and X-ray fluorescence computed tomography (XFCT). The NPs are synthesized via a one-pot polyol hot injection route, in diethylene glycol. In vivo preclinical studies demonstrate the possibility of correlative bioimaging with these contrast agents. The complementarity allows accurate localization, provided by the high contrast of the soft tissues in MRI combined with the elemental selectivity of XFCT, leading to NP detection with high specificity and resolution. We envision that this multimodal imaging could find future applications for early tumor diagnosis, improved long-term treatment monitoring, and enhanced radiotherapy planning.

Graphical abstract: XFCT-MRI hybrid multimodal contrast agents for complementary imaging

Supplementary files

Article information

Article type
Paper
Submitted
20 Oct 2022
Accepted
28 Dec 2022
First published
28 Dec 2022
This article is Open Access
Creative Commons BY license

Nanoscale, 2023,15, 2214-2222

XFCT-MRI hybrid multimodal contrast agents for complementary imaging

G. M. Saladino, C. Vogt, B. Brodin, K. Shaker, N. I. Kilic, K. Andersson, M. Arsenian-Henriksson, M. S. Toprak and H. M. Hertz, Nanoscale, 2023, 15, 2214 DOI: 10.1039/D2NR05829D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements